Table 2.
Summary of Clinicopathological characteristics of the eligible studies
| Study | Patients factor | Tumor factor | AT, % | Matched factora | ||||
|---|---|---|---|---|---|---|---|---|
| No. of participants (female, %) | Age, mean (SD), y | Size, mean (SD), cm | Site (head, %) | VR, % | CA19-9, mean (SD), U/ml | |||
| Barbier et al. [23] |
NAT: 88 SF:85 |
65 (39–81)g 64 (37–79) |
NA |
100 100 |
16 30 |
> 350 (16)b > 350 (15) |
0 NA |
1, 4, 5, 6 |
| Papalezova et al. [24] |
NAT: 144 (46) SF: 92 (47) |
64 (12) 65 (12) |
2.5 (1.2) 2.1 (1.3) |
100 100 |
18 22 |
NA |
33 66 |
1, 2, 4, 5 |
| Tajima et al. [25] |
NAT: 13 (46) SF: 21 (33) |
63 (51–77)g 66 (52–80) |
NA |
69 52 |
100 100 |
NA | NA | 1, 2, 4, 5 |
| Cho et al. [26] |
NAT: 30 (47) SF: 21 (52) |
59.57 (8.6) 60.76 (10.8) |
2.6 (0.9) 2.6 (0.8) |
87 86 |
43 38 |
1189 (2482) 540 (840) |
50 62 |
1, 2, 3, 4, 5, 6, 7 |
| Jiang et al. [27] |
NAT: 112 (33) SF: 120 (43) |
45.9 (9.8) 45.5 (9.3) |
NA |
88 80 |
NA |
211 (46) 284 (56) |
0 0 |
1, 2, 4, 6, 7 |
| Patel et al. [28] |
NAT: 17 (47) SF: 13 (31) |
60 (39–72)g 71 (42–82) |
NA |
88 85 |
NA | NA |
82 77 |
1, 2, 4, 7 |
| Roland et al. [30] |
NAT: 222 (44) SF: 85 (40) |
64 (35–86)g 64 (40–85) |
NA |
92 87 |
31 27 |
< 1000 (74)b < 1000 (66) |
11 68 |
1, 2, 4, 5, 6 |
| Lee et al. [29] |
NAT: 30 (60) SF: 28 (50) |
61.7 (8.8) 62.9 (9.6) |
2.7(0.7) 2.6(0.7) |
90 96 |
70 29 |
816 (1452) 504 (830) |
73 75 |
1, 2, 3, 6, 7 |
| Sho et al. [31]c |
NAT: 85 (45) SF: 99 (47) |
65.7 (8.9) 68.9 (10) |
NA | NA | NA | NA |
61 48 |
2, 7 |
| Golcher et al. [36] |
NAT: 33 (45) SF: 33 (48) |
62.5 (33–76) 65.1 (46–73) |
NA |
100 100 |
NA 22 |
NA |
37 30 |
1, 2, 4, 7 |
| Hirono et al. [32] |
NAT: 46 SF: 124 |
69 (41–90)g |
3 (1.1–7.1)g 2.9 (1.2–8.5) |
43 56 |
60 42 |
NA |
53 64 |
3, 4, 5, 7 |
| Masui et al. [33] |
NAT: 18 (56) SF: 19 (68) |
63 (43–73)g 66 (56–80) |
3.3 (1.8–5)g 3.2 (1.7–7.5) |
72 68 |
47 37 |
102 217 |
78 84 |
1, 2, 3, 4, 5, 6, 7 |
| Ielpo et al. [3]d |
NAT: 45 (36) SF: 36 (42) |
62 (42–81)f 64 (46–78) |
7.5 6.8 |
71 58 |
35 36 |
1754 1621 |
61 58 |
1, 2, 3, 4, 5, 6, 7 |
| Murakami et al |
NAT: 52 (33) SF: 25 (28) |
> 67 (48)b > 67 (60) |
≥ 37 (52)b ≥ 37 (34) |
67 84 |
62 57 |
> 150 (52)b > 150 (52) |
80 48 |
1, 2, 4, 6 |
| Fujii et al. [34]e |
NAT: 40 (48) SF: 233 (37) |
65 (36–79)g 67 (35–88) |
2.9 (1.5–5.2)g 2.5 (0.8–5.6) |
100 100 |
25 32 |
143 148 |
67 66 |
1,2,3,4,5,6,7 |
|
NAT: 27 (56) SF: 102 (48) |
68 (47–78)g 66 (39–83) |
3 (1.8–3.9)g 3.3 (1.5–7) |
100 100 |
96 95 |
323 259 |
39 44 |
1, 2, 3, 4, 5, 6, 7 | |
|
NAT: 21 (52) SF: 81 (37) |
68 (47–76)g 65 (42–82) |
3.5 (2.6–4.6)g 3 (2–6) |
100 100 |
79 87 |
286 218 |
46 43 |
1, 2, 3, 4, 5, 6, 7 | |
| Jang et al. [9] |
NAT: 27 (37) SF: 23 (35) |
59.4 (8.4) 58.9 (11.3) |
3.4 (0.8) 3.5 (0.9) |
85 74 |
35 28 |
1042 (2465) 1258 (2540) |
52 57 |
1, 2, 3, 4, 5, 6, 7 |
| Reni et al. [12] |
NAT: 32 (22) SF: 26 (46) |
64 (39–75)g 65 (37–74) |
2.0 (0–6.0)g 2.5 (1.5–5.0) |
88 96 |
0 9 |
173 (43–4510) 179 (39–3337) |
72 65 |
1, 2, 3, 4, 5, 6, 7 |
Abbreviations: NAT neoadjuvant therapy, SF surgery first, AT adjuvant therapy, VR vascular resection, NA not available
aFactors matched with NAT and SF: 1, age; 2, sex; 3, initial tumor size; 4, tumor location; 5, vascular resection; 6, initial CA19-9 level; 7, AT
bReported as range (percentage, %)
cThe study by Sho et al. has 2 independent data sets (1 data set for RPC and 1 data set for BRPC)
dThe study by lelpo et al. has 1 data set for RPC/BRPC, but it has 2 data subsets (1 data subset for RPC and 1 data subset for BRPC)
eThe study by Fujii et al. has 3 independent data sets (1 data set for RPC, 1 data set for BRPC, and 1 data set for RPC/BRPC)
fReported as mean (range)
gReported as median (range)